tbuckley/cabot-search huggingface dataset:
The Albany Medical Annals.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fiftieth Annual of Virchow's Promotion.From Our Special Correspondent.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE STATE SOCIETIES.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Disseminated intravascular coagulation and hepatic necrosis. Complications of infectious mononucleosis
Authors: L. L. Pelletier
Journal: JAMA (1976)

AN INTRACTABLE bleeding diathesis, disseminated intravascular coagulation (DIC), and infarction of the liver developed in a middle-aged man with infectious mononucleosis. The striking histologic finding in this case was massive coagulative periportal hepatic necrosis. <h3>Report of a Case</h3> A 48-year-old man was admitted to the University of Kansas Medical Center in March 1973, because of somnolence, asterixis, and jaundice. Five weeks earlier he had noted fever, malaise, and pain on swallowing. He then consulted his personal physician, who prescribed saline gargles and ampicillin sodium. Anasarca, dyspnea, and orthopnea developed two days later. A diuretic and dexamethasone sodium phosphate were administered, with resolution of his symptoms. After the discontinuance of dexamethasone therapy, a 40-C (104-F) temperature, sore throat, malaise, and weakness recurred and persisted while the patient continued to receive ampicillin. Progressive jaundice and somnolence developed two days before admission to our institution. The patient's medical history had been unremarkable. At
Timing of Postmenopausal Estrogen for Optimal Bone Mineral Density&lt;subtitle&gt;The Rancho Bernardo Study&lt;/subtitle&gt;
Authors: Diane L. Schneider
Journal: JAMA (1997)

<h3>Objective.</h3> —To determine the effect of the timing of initiation and the duration of postmenopausal estrogen therapy on bone mineral density (BMD). <h3>Design.</h3> —Cross-sectional study. <h3>Setting.</h3> —White, middle-class to upper middle-class community-dwelling women. <h3>Participants.</h3> —A total of 740 women aged 60 to 98 years who participated in a study of osteoporosis. <h3>Measurements.</h3> —Questionnaire, validated medication use, and height and weight. Bone mineral density at the ultradistal radius and midshaft radius using single-photon absorptiometry (SPA) and at the hip and lumbar spine using dual-energy x-ray absorptiometry (DEXA). <h3>Results.</h3> —Of the 740 women, 69% had used oral estrogen after menopause and 30% were current users. Five groups of estrogen use were identified: never users, past users who started at menopause, past users who started after age 60 years, current users who started after age 60 years, and current users who started at menopause. At all 4 bone sites, current users who started at menopause had the highest BMD levels, which were significantly higher than never users or past users who started at menopause (with 10 years' duration of use). These differences persisted after controlling for all major risk factors for osteoporosis. Among current users, there was no significant difference in BMD levels at any site between those who started estrogen at menopause (with 20 years of use) and those who started after age 60 years (with 9 years of use). <h3>Conclusions.</h3> —Estrogen initiated in the menopausal period and continued into late life is associated with the highest bone density. Nevertheless, estrogen begun after age 60 years and continued appears to offer nearly equal bone-conserving benefit.
Centenary of the Death of John Hunter.—
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Retraction: Decline in NRF2-regulated Antioxidants in Chronic Obstructive Pulmonary Disease Lungs Due to Loss of Its Positive Regulator, DJ-1; Heightened Endoplasmic Reticulum Stress in the Lungs of Patients with Chronic Obstructive Pulmonary Disease: The Role of Nrf2-Regulated Proteasomal Activity
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

The American Journal of Respiratory and Critical Care Medicine is retracting two articles with the agreement of the authors (despite repeated attempts, one coauthor could not be located): "Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1" (1); and "Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity" ( 2).An Expression of Concern has been previously published regarding these two articles (3).The authors provided the Journal with a statement that includes results from an official investigation conducted by the Johns Hopkins School of Public Health.The statement enumerates problems with figures in the 2008 article (1).It states that Figures 1C and 2B contain separate blot images spliced together to represent one image without appropriate demarcation.Additionally, Figures 1C and 2B, representing two different experiments, contain the same glyceraldehyde phosphate dehydrogenase (GAPDH) panel.Figures 5A and 5D, representing two different experiments, contain portions of the same GAPDH panel.The NQO1 (NADPH:quinone oxidoreductase 1) and GAPDH panels in Figure 6B contain separate blot images spliced together to represent one image without appropriate demarcation.The statement also lists problems with the figures in the 2009 article (2).It states that Figures 1A and 2A contain GAPDH panels that do not align with the lanes in the panels above.Additionally, Figures 1A and 2A, representing two different experiments, contain the same GAPDH panel.Figure 3A, representing mouse samples, contains a portion of the GAPDH panel from Figure 4C representing human samples.Figure 4C contains two separate blot images representing normal and moderate chronic obstructive pulmonary disease without appropriate demarcation.
Risk of Hypoglycemia With Antihypertensive Medication
Authors: Edeltraut Garbe
Journal: JAMA (1997)

<h3>To the Editor.</h3> —We read with interest the study by Dr Shorr and colleagues, which suggests that antihypertensive drug therapy has little impact on the risk of hypoglycemia in older diabetic patients. Three reasons may have led to these results. First, the authors express concern about the possibility of "confounding by contraindication" in relation to β-blocker use, which may have resulted in an underestimate of the risk. The concern is appropriate, since β-blockers have a well-recognized hypoglycemia-masking effect, and caution is usually recommended regarding their use in diabetic patients. A history of hypoglycemic episodes may reduce the likelihood that a patient will be prescribed β-blockers and is a risk factor for future episodes of hypoglycemia. In the Diabetes Control and Complications Trial (DCCT), the number of prior episodes of hypoglycemia was the strongest predictor of the risk of future hypoglycemic episodes in insulin-treated diabetic patients.<sup>2</sup>It would have been interesting to measure
Choice of anesthetic technique in patients with acute pulmonary disease
Authors: W. K. Hamilton
Journal: JAMA (1966)

A 75-year-old woman was admitted to the hospital two days following an intertrochanteric fracture of her left hip. She had been hospitalized in another hospital for the two-day period. Past history revealed an episode of pneumonia of the middle lobe of the right lung four years prior to admission and pneumonia of the lower lobe of the right lung six months prior to admission. She had had asthma for several years. She had daily a productive cough producing thick tenacious sputum, quantity unknown; she denied having dyspnea. Physical examination revealed a reasonably healthy old woman. There were rales throughout her left lung field, and chest x-ray films revealed a marked tracheal deviation and apparent near-total collapse of the left lung (Figure). On the basis of traditional concepts that inhalation anesthesia may be injurious to the lungs and not tolerated well by patients with lung disease, regional anesthesia was strongly recommended
Antiarrhythmic Agents
Authors: David H. Spodick
Journal: JAMA (1973)

In just 115 pages of text, Drs. Moss and Patton have carefully condensed the current understanding of the physiology, pharmacology, and practical therapeutics of managing cardiac rhythm disturbances. Section I (the first three chapters) covers electrophysiology, mechanisms producing arrhythmias, and pharmacodynamic principles. Section II devotes a chapter to each of ten antiarrhythmic agents, including such "household" items as quinidine, procainamide, propranolol, digitalis glycosides, lidocaine, diphenylhydantoin, isoproterenol, and atropine, plus the less familiar bretylium. These are individually described on the basis of chemistry, pharmacology, and electrophysiology, followed by therapeutic uses and adverse reactions. Each discussion is keyed to the principles and illustrations that had been presented in section I. Chapters 14 and 15 form section III. They cover, respectively, a comparison of the ten antiarrhythmic agents and the management of refractory dysrhythmias. Excellent comparative tables are included, and there is one showing relative costs of medications. The appendix lists their proprietary
Abstract 3856: MTLCEBPA, a drug candidate for hepatocellular-carcinoma enhances efficacy of Sorafenib
Authors: Nagy A. Habib, Kai-Wen Huang, Vikash Reebye, Mikael Sodergren, John Rossi
Journal: Cancer Research (2019)

Abstract MTLCEBPA, a non-toxic therapeutic oligonucleotide formulated inside SMARTICLES (liposomal nanoparticles) is currently under a Phase I study for patients with advanced hepatocellular carcinoma (HCC). We have demonstrated in multiple in vivo liver disease models that MTLCEBPA can improve liver function and inhibit HCC tumor growth. Here we show that upregulation of hepatic CEBPA expression by MTLCEBPA enhances the effects of Sorafenib in a (Diethylnitrosamine) DEN induced cirrhotic HCC rat model by significantly reducing liver tumor volume after only two weeks of combination treatment when compared to untreated control or single agent treatment only. In this study, we established cirrhosis and HCC by exposing male Wistar rats to DEN for 6 weeks. Animals were randomized into 5 groups comprising of: 1. PBS control; 2. MTL-CEBPA treatment (TIW at 3mg/kg) for one week; 3. MTL-CEBPA treatment (TIW at 3mg/kg) for two weeks; 4. Sorafenib TIW at 10mg/kg for two weeks; and 5. MTLCEBPA at 3mg/kg at week one combined with Sorafenib 10mg/kg at week 2 group. The results here indicate that Sorafenib combined with MTLCEBPA significantly inhibits tumor growth when compared to single agent treatment. Tumor sizes averaged at 644.7mm3 (± 88.57) in group 1 compared to 326mm3 (± 53.05) in group 2; 199.7mm3 (± 54.73) in group 3 and 299.5mm3 (± 77.1) in group 4. In combination treatment (group 5) the tumor sizes averaged at 101.3mm3 (± 37.48). Serum AFP change (posttreatment values - pre-treatment) was more prominent in the MTLCEBPA/Sorafenib combination treatment (group 5) where there was a 4-fold reduction in values after treatment when compared to control groups 1-4. Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and total bilirubin remained unchanged across all the treatment groups suggesting no deterioration in liver function during the study period. These results suggest that MTLCEBPA improved the efficacy of Sorafenib in this DEN induced HCC model, indicating a promising therapeutic option for advanced HCC patients who can no longer be treated with potentially more effective local therapies. Citation Format: Nagy A. Habib, Kai-Wen Huang, Vikash Reebye, Mikael Sodergren, John Rossi. MTLCEBPA, a drug candidate for hepatocellular-carcinoma enhances efficacy of Sorafenib [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3856.
Error in Corresponding Authorship
Authors: Eduardo Nagore, Rajiv Kumar
Journal: JAMA Dermatology (2019)

In Reply We are grateful to Adler and colleagues for their interest in our published study. 1 We do agree that our results do not rule out the role of tumor mutational profile in the lymphatic spread of melanoma.On the contrary, our data support their results that indicate the prognostic value of BRAF mutation for lymphatic spread of melanomas.In our series, BRAF mutation (hazard ratio [HR], 1.9; 95% CI, 1.2-3.2;P = .005)was associated with an increased risk of lymphatic spread in univariate analysis (see eTable 2 in the Supplement of the article) 1 ; thus, the effect of the association is in the same direction as in the study by Adler et al. 2 However, the association did not remain statistically significant after multivariate analysis.The association between BRAF and TERT promoter mutations and hematogenous spread remained statistically significant even after multivariate analysis, indicating that those mutations are greater risk factors for hematogenous spread than for lymphatic spread.In their study, Adler et al 2 did not conclusively show that the mutant tumors were markers of increased risk of hematogenous spread.However, it should be highlighted that the number of patients developing distant metastasis was low (26 of 344 patients) and the direction of the association (adjusted HR, 1.93; 95% CI, 0.78-4.82;P = .16)was in accordance with our results. 1,2Simultaneous occurrence of BRAF and TERT promoter mutations has also been associated with increased growth rate of melanomas. 3The overexpression of genes involved in proliferation has been consistently shown to be associated with decreased melanoma-specific survival. 4In contrast to tumor proliferative markers such as tumor mitotic rate, the mutational status might represent an objective measure of tumor proliferative capacity.Therefore, our results mainly suggest that TERT promoter and BRAF mutational status, as objective markers of such tumor proliferative capacity, can be helpful to identify patients with stage I to II melanoma at an increased risk of hematogenous spread and who are possible candidates for adjuvant therapy.
Abstract 3685: Reduced Systemic Arterial Compliance is an Independent Predictor of Mortality in Patients with Diabetes
Authors: Dania Mohty, Philippe Pibarot, Paul Poirier, Jean G. Dumesnil
Journal: Circulation (2007)

Background: Diabetes is associated with accelerated vascular calcification and stiffening of the arteries. Reduced systemic arterial compliance (SAC) is regarded as a major factor in the development of hypertension, contributing to increased left ventricular afterload and myocardial oxygen demand and reduced coronary flow reserve. We thus hypothesized that reduced SAC is an independent predictor of mortality in patients with diabetes. Methods: We retrospectively analyzed data of 528 consecutive patients with type 2 diabetes who had a Doppler-echocardiographic exam in our institution. Blood pressure was measured in all patients at the time of echocardiography. SAC was calculated as the ratio of stroke volume index to arterial pulse pressure. Results: Follow up was completed in 97% of patients and mean follow-up time was 2.9±1.2 years. Mean age was 66±11 years with 68% males and 68% with coronary artery disease (CAD). Fifty percent of the patients had markedly reduced SAC on the basis of the cut-off value (SAC &lt;0.6 ml/m 2 /mmHg) previously reported to be associated with adverse outcome in patients with hypertension. Patients with reduced SAC were significantly older (68±11 vs. 65±10, p=0.002) and had a higher prevalence of hypertension (78 vs. 22%, p&lt;0.0001) and lower LV ejection fraction (51±15 vs. 57±13%, p=0.001). The prevalence of male gender, CAD, and obesity assessed with body mass index (BMI) was similar in patients with reduced SAC compared to those with higher SAC values. Five-year survival was significantly lower in patients with reduced SAC (68±5 vs. 87±4%, p&lt;0.005). After adjusting for age, gender, LV ejection fraction, CAD, BMI, and blood pressure, reduced SAC remained a powerful and independent predictor of total mortality (Hazard ratio: 1.70 95% Confidence interval: 1.14 –2.58; p=0.008). Conclusion : Reduced SAC is encountered frequently in patients with type 2 diabetes and is a major risk factor for total mortality in this population. The SAC, which is easily measurable in the context of routine echocardiographic exam, should be taken into consideration when evaluating these patients with regards to prognosis and treatment. Funded by: Québec Heart Institute Foundation
Treatment of burns and donor sites with human allogeneic keratinocytes grown on acellular pig dermis
Authors: E. MATOUŠKOVÁ, S. BUČEK, D. VOGTOVÁ, P. VESELýA, A. CHALOUPKOVÁ, L. BROŽ, H. SINGEROVÁ, L. PAVLÍKOVÁ, R. KÖNIGOVÁ
Journal: British Journal of Dermatology (1997)

The absence of a dermal component predisposes cultured epidermal sheets to instability, contractibility, and makes them difficult to handle. In order to overcome these drawbacks, we developed recombined human/pig skin (RHPS) composed of human keratinocytes cultured on cell-free pig dermis. The original intention to prepare a permanent skin substitute composed of xenodermis and autologous epidermis was not achieved, but it has been proved that RHPS can serve as an effective, ready to use keratinocyte delivery system when applied'upside-down', i.e. with epidermal cells facing the wound surface. The keratinocyte layer establishes a direct contact with the wound bed, while the dermal layer mechanically protects the wound. Twenty deep dermal burns were grafted with RHPS: 13 (65%) healed completely in 4–14 days, three (15%) healed partially and four (20%) did not heal. Of five full thickness burn wounds only one healed after repeated RHPS grafting within 18 days. Thirty-one (100%) donor sites treated with any of the three forms of RHPS, subconfluent, confluent meshed or confluent unmeshed, healed within 6–8 days compared with 14–18 days in control sites. Seven donor sites (100%) of immunodeficient patients with prolonged wound healing epithelialized in 7–10 days under RHPS compared with 32–90 days in areas treated with tulle gras and dry gauze.